Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 10,717,290 | 10,989,860 | 11,304,000 | 10,949,970 | 10,543,900 |
| Cost of Goods | 2,843,510 | 2,985,899 | 3,220,770 | 2,683,000 | 2,873,790 |
| Gross Profit | 7,587,930 | 7,992,549 | 8,230,870 | 8,284,030 | 7,668,790 |
| Operating Expenses | 4,872,180 | 4,281,628 | 4,968,939 | 5,483,520 | 4,919,050 |
| Operating Income | 3,002,110 | 3,723,232 | 3,115,061 | 2,783,450 | 2,751,850 |
| Other Income | -50,210 | -1,044,452 | 13,829 | -185,310 | 1,193,010 |
| Pre-tax Income | 2,951,900 | 2,678,780 | 3,128,890 | 2,598,140 | 3,944,860 |
| Income Tax | 768,210 | 655,960 | 802,770 | 726,240 | 1,408,880 |
| Net Income Continuous | 2,138,616 | 1,971,812 | 2,191,000 | 1,802,183 | 2,441,830 |
| Net Income | $2,138,616 | $1,971,812 | $2,191,000 | $1,802,183 | $2,441,830 |
| EPS Basic Total Ops | 1.08 | 0.99 | 1.10 | 0.89 | 1.20 |
| EPS Basic Continuous Ops | 1.08 | 0.99 | 1.10 | 0.89 | 1.20 |
| EPS Diluted Total Ops | 1.06 | 0.98 | 1.08 | 0.88 | 1.19 |
| EPS Diluted Continuous Ops | 1.08 | 0.98 | 1.08 | 0.89 | 1.19 |
| EBITDA(a) | $3,379,150 | $4,524,542 | $4,033,281 | $3,546,360 | $2,959,980 |